يعرض 1 - 10 نتائج من 44 نتيجة بحث عن '"Zemanick, Edith T."', وقت الاستعلام: 0.94s تنقيح النتائج
  1. 1
  2. 2
    دورية أكاديمية
  3. 3
    دورية أكاديمية
  4. 4
  5. 5
    دورية أكاديمية
  6. 6
    دورية أكاديمية
  7. 7
    دورية أكاديمية
  8. 8
    دورية أكاديمية
  9. 9
    دورية أكاديمية
  10. 10
    دورية أكاديمية

    وصف الملف: application/pdf

    العلاقة: Martiniano, Stacey L.; Esther, Charles R.; Haworth, Charles S.; Kasperbauer, Shannon H.; Zemanick, Edith T.; Caverly, Lindsay J. (2020). "Challenging scenarios in nontuberculous mycobacterial infection in cystic fibrosis." Pediatric Pulmonology 55(2): 521-525.; https://hdl.handle.net/2027.42/153589Test; Pediatric Pulmonology; Cystic Fibrosis Foundation. Patient Registry Annual Data Report. 2017.; Gilljam M, Berning SE, Peloquin CA, Strandvik B, Larsson LO. Therapeutic drug monitoring in patients with cystic fibrosis and mycobacterial disease. Eur Respir J. 1999; 14 ( 2 ): 347 ‐ 351.; Olivier KN, Weber DJ, Lee JH, et al. Nontuberculous mycobacteria. II: nested‐cohort study of impact on cystic fibrosis lung disease. Am J Respir Crit Care Med. 2003; 167: 835 ‐ 840.; Esther CR, Kerr A, Gilligan PH. Detection of Mycobacterium abscessus from deep pharyngeal swabs in cystic fibrosis. Infect Control Hosp Epidemiol. 2015; 36: 618 ‐ 619.; Guimbellot JS, Acosta EP, Rowe SM. Sensitivity of ivacaftor to drug‐drug interactions with rifampin, a cytochrome P450 3A4 inducer. Pediatr Pulmonol. 2018; 53 ( 5 ): E6 ‐ E8.; Ronchetti K, Tame JD, Paisey C, et al. The CF‐Sputum Induction Trial (CF‐SpIT) to assess lower airway bacterial sampling in young children with cystic fibrosis: a prospective internally controlled interventional trial. Lancet Respir Med. 2018; 6: 461 ‐ 471.; Hoppe JE, Towler E, Wagner BD, Accurso FJ, Sagel SD, Zemanick ET. Sputum induction improves detection of pathogens in children with cystic fibrosis. Pediatr Pulmonol. 2015; 50: 638 ‐ 646.; Griffith DE, Aksamit T, Brown‐Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007; 175: 367 ‐ 416.; Floto RA, Olivier KN, Saiman L, et al. US cystic fibrosis foundation and European Cystic Fibrosis Society consensus recommendations for the management of nontuberculous mycobacteria in individuals with cystic fibrosis. Thorax. 2016; 71: i1 ‐ i22.; Martiniano SL, Sontag MK, Daley CL, Nick JA, Sagel SD. Clinical significance of a first positive nontuberculous mycobacteria culture in cystic fibrosis. Ann Am Thorac Soc. 2014; 11: 36 ‐ 44.